Anti-Osteoprotegerin 抗体 (ab9986)
Key features and details
- Rabbit polyclonal to Osteoprotegerin
- Suitable for: WB
- Reacts with: Human
- Isotype: unknown
製品の概要
-
製品名
Anti-Osteoprotegerin antibody
Osteoprotegerin 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to Osteoprotegerin -
由来種
Rabbit -
アプリケーション
適用あり: WBmore details -
種交差性
交差種: Human -
免疫原
Recombinant fragment corresponding to Human Osteoprotegerin.
Database link: O00300 -
特記事項
This product is no longer batch tested in IHC, for an IHC validated antibody please see ab124820
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Lyophilized:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary. -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
バッファー
No preservative, sterile filtered -
Concentration information loading...
-
精製度
Immunogen affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
unknown -
軽鎖の種類
unknown -
研究分野
関連製品
-
Compatible Secondaries
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab9986の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 46 kDa).
To detect hOPG by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hOPG is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. |
特記事項 |
---|
WB
Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 46 kDa). To detect hOPG by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hOPG is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. |
ターゲット情報
-
機能
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. -
組織特異性
Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung. -
関連疾患
Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal. -
配列類似性
Contains 2 death domains.
Contains 4 TNFR-Cys repeats. -
翻訳後修飾
N-glycosylated. Contains sialic acid residues.
The N-terminus is blocked. -
細胞内局在
Secreted. - Information by UniProt
-
参照データベース
- Entrez Gene: 4982 Human
- Omim: 602643 Human
- SwissProt: O00300 Human
- Unigene: 81791 Human
-
別名
- MGC29565 antibody
- OCIF antibody
- OPG antibody
see all
画像
-
All lanes : Anti-Osteoprotegerin antibody (ab9986) at 1 µg/ml
Lane 1 : U2OS (Human osteosarcoma cell line) Whole Cell Lysate
Lane 2 : HEK293 (Human embryonic kidney cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 46 kDa
Observed band size: 56 kDa why is the actual band size different from the predicted?
Additional bands at: 32 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 150 seconds
Osteoprotegerin contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
プロトコール
データシートおよび資料
-
Datasheet download
参考文献 (18)
ab9986 は 18 報の論文で使用されています。
- Lima IFP et al. RANK, RANKL, and OPG in Dentigerous Cyst, Odontogenic Keratocyst, and Ameloblastoma: A Meta-Analysis. Braz Dent J 32:16-25 (2021). PubMed: 33913997
- Zhang JR et al. TNFRSF11B Suppresses Memory CD4+ T Cell Infiltration in the Colon Cancer Microenvironment: A Multiomics Integrative Analysis. Front Immunol 12:742358 (2021). PubMed: 34938284
- Luo Y et al. Disordered metabolism in mice lacking irisin. Sci Rep 10:17368 (2020). PubMed: 33060792
- Sun Y et al. Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway. Int J Endocrinol 2020:8821077 (2020). PubMed: 33488706
- Li S et al. PKC-d deficiency in B cells displays osteopenia accompanied with upregulation of RANKL expression and osteoclast-osteoblast uncoupling. Cell Death Dis 11:762 (2020). PubMed: 32938907